Medical history and clinical examinations are insufficient to exclude vertical human immunodeficiency virus transmission in healthy, at-risk adolescents.

The article focuses on the lack of paediatric licensing in all the marketed drugs in paediatric oncology. It discusses the evaluation of the European Union (EU) Paediatric Regulation report by the European Medicines Agency (EMA), wherein it was proved that research was concluded by adult medicine development and economic incentives.